However, a recent phase III clinical trial (CONTRAST-3) of otilimab, an anti-GM-CSF antibody, in patients with RA failed to demonstrate its significant superiority over placebo or non-inferiority to the anti-IL-6 receptor antibody, sarilumab (Taylor et al., 2023). The gene discussed is CSF2; the disease is rheumatoid arthritis.